Claudin-5 is an integral membrane protein and a critical component of endothelial tight junctions that control paracellular permeability. Claudin-5 is expressed at high levels in the brain vascular endothelium. Estrogens have multiple effects on vascular physiology and function. The biological actions of estrogens are mediated by two different estrogen receptor (ER) subtypes, ER alpha and ER beta. Estrogens have beneficial effects in several vascular disorders. Recently we have cloned and characterized a murine claudin-5 promoter and demonstrated 17beta-estradiol (E2)-mediated regulation of claudin-5 in brain and heart microvascular endothelium on promoter, mRNA and protein level. Sequence analysis revealed a putative estrogen response element (ERE) and a putative Sp1 transcription factor binding site in the claudin-5 promoter. The aim of the present study was to further characterize the estrogen-responsive elements of claudin-5 promoter. First, we introduced point mutations in ERE or Sp1 site in À500/+111 or in Sp1 site of À268/+111 claudin-5 promoter construct, respectively. Basal and E2-mediated transcriptional activation of mutated constructs was abrogated in the luciferase reporter gene assay. Next, we examined whether estrogen receptor subtypes bind to the claudin-5 promoter region. For this purpose we performed chromatin immunoprecipitation assays using anti-estrogen receptor antibodies and cellular lysates of E2-treated endothelial cells followed by quantitative PCR analysis. We show enrichment of claudin-5 promoter fragments containing the ERE-and Sp1-binding site in immunoprecipitates after E2 treatment. Finally, in a gel mobility shift assay, we demonstrated DNA-protein interaction of both ER subtypes at ERE. In summary, this study provides evidence that both a non-consensus ERE and a Sp1 site in the claudin-5 promoter are functional and necessary for the basal and E2-mediated activation of the promoter.
Introduction
The blood-brain (BBB) barrier plays a crucial role in the central nervous system (CNS) homeostasis. Changes of BBB integrity are common pathological features in different neuroinflammatory and neurodegenerative diseases of the CNS, so research that aims to clarify the molecular structure and molecular mechanisms of BBB regulation may open new avenues for developing future therapeutic strategies of CNS disorders. The BBB is built of endothelial cells sealed with tight junctions (TJ), which together with pericytes are surrounded by a basal lamina. Outside of the basal lamina astrocytic endfeet build a tight network having structural and regulatory functions (reviewed in (Abbott et al., 2010) ). TJ are built through protein complexes composed of transmembrane, cytoplasmic and cytoskeletal proteins (Forster, 2008) . Transmembrane proteins building the TJ are occludin, tricellulin and claudins. One of the prominently expressed claudins at the BBB is claudin-5 (Morita et al., 1999) . Tight transcriptional and posttranslational regulation of claudin-5 takes place in physiological and pathological processes. Claudin-5 knockout mice show increased permeability of the BBB for molecules smaller than 800 Dalton and die several hours after birth (Nitta et al., 2003) . Down-regulation of claudin-5 and elevation of BBB function were observed in a mouse model of multiple sclerosis (Errede et al., 2012) , due to a HIV-1 infection (Andras et al., 2005) ; or at the hypoxic BBB as a result of stroke (Kleinschnitz et al., 2011) . Over-expression of claudin-5 leads to an increase of barrier tightness (Ohtsuki et al., 2007) and has been demonstrated to have beneficial effects in the outcome of stroke or traumatic brain injury (Kleinschnitz et al., 2011; Thal et al., 2012) . Both subtypes of estrogen receptor, ERa and ERb are expressed in the vasculature and in the CNS (Walter et al., 1985; Kuiper et al., 1996; Nilsson and Gustafsson, 2011) . In the unliganded state, ERs are present in the cells in inactive form in the cytoplasm. After binding of the ligand, a steroid hormone 17b-estradiol (E2), ERs build homo-or heterodimers and translocalize into the nucleus, where they bind at the palindromic DNA sequences, so called estrogen response elements (EREs) in the promoter region of target genes leading to the activation of gene expression Mangelsdorf et al., 1995) . ER can also activate the transcription of genes binding to other transcription factors such as Sp1 or Ap1 (Kushner et al., 2000; Safe and Kim, 2004) . Moreover, many different cofactors and inhibitors are involved in estrogen-mediated gene regulation (Shibata et al., 1997) . Although both ERa and ERb are expressed in endothelial and smooth muscle cells of blood vessels, most of E2 effects on the endothelium, such as re-endothelialization (Brouchet et al., 2001 ) and endothelial nitric oxide production (Darblade et al., 2002) are ERa-, but not ERb mediated. In previous studies we cloned the murine claudin-5 promoter and characterized its estrogen-mediated regulation (Burek and Forster, 2009; Burek et al., 2010) . E2 treatment of mouse brain and heart microvascular endothelial cells leads to an increase in transendothelial electrical resistance and in claudin-5 mRNA and protein level. These results were confirmed in ovariectomized mice and in ERb-knockout mice giving a proof for ERb-mediated regulation of claudin-5 in endothelial cells (Burek et al., 2010) . Analysis of the claudin-5 promoter sequence (GenBank Accession number EU623469) revealed a non-consensus ERE at the position À303/À289 (5 0 -GGGTCATGCTGCTAA-3 0 ) and a GC-rich sequence, a Sp1 binding site at the position À57/À47 (5 0 -TGGGGGCAGAG-3 0 ) (Burek and Forster, 2009 ). So we raised the hypothesis that those sites might be responsible for E2-mediated regulation of claudin-5. The aim of the present study was to further characterize the molecular mechanism of E2-mediated regulation of claudin-5 and to identify the ER-binding sites in the claudin-5 promoter. For this we performed reporter gene assays using claudin-5 promoter with mutated potential ER binding sites, we analyzed binding of ER to the claudin-5 promoter chromatin immunoprecipitation assays (ChIP) using anti-ERa and ERb antibody, and showed the complexes in elecritc mobility shift assay (EMSA). The results of this study suggest that both ER subtypes are involved in claudin-5 regulation cooperatively through both studied promoter elements, ERE and GC-rich sequence.
Materials and methods

Chemicals
17b-estradiol (E2) was purchased from Sigma. Stock solution was prepared in dimethyl sulfoxide (DMSO) and kept at À20°C. Desired dilution was made shortly before the experiment in cell culture medium. The final concentration of DMSO in the treatment medium was lower than 0.01% (v/v).
Plasmids
Cloning of the mouse claudin-5 promoter (GenBank Accession number EU623469) into the pGL3-basic vector (Promega) was previously described (Burek and Forster, 2009) . Constructs with À500/ +111 and À268/+111 fragments of wild type claudin-5 promoter cloned upstream of luciferase reporter gene were used in this study.
Site-directed mutagenesis
Site-directed mutagenesis was performed using QuikChange II Site-Directed Mutagenesis Kit (Agilent) according to the manufacturer's instructions. The pGL3-basic À500/+111 and À268/+111 constructs containing the wild type claudin-5 promoter were used for generation of mutated forms. The primer (Eurofins MWG Operon) complementary to each other and containing the desired nucleotide changes were as follows: mutERE1: 5 0 -GTGTAGGT TAGGTTTCATGCTTCTAACAGTGGA-3 0 and 5 0 -TCCACTGTTAGAAGCA TGAAACCTAACCTACAC-3 0 ; mutERE2: 5 0 -GTGTAGGTTAGGTTTCATG CTGCTAA CAGTGGA-3 0 and 5 0 -TCCACTGTTAGCAGCATGAAACCTA ACCTACAC-3 0 ; mutSp1: 5 0 -TGCGCCCTGGTGACAGAGTCCGCCCCCGA-3 0 and 5 0 -TCGGGGGCGGACTCTG TCACCAGGGCGCA-3 0 . MutSp1 primer was used with both À500/+111 and À268/+111 constructs for a generation of a À500/+111 construct with a functional ERE and mutated Sp1 and for a generation of À268/+111 construct containing no ERE and a mutated form of Sp1 binding site. MutERE1 and mutERE2 were used to generate ERE mutations with 2-or 3-nucleotide changes. Plasmids were screened by restriction digestion and the mutations were confirmed by sequencing (Eurofins MWG Operon).
Cell culture
Mouse brain microvascular endothelial cells, cEND were isolated and immortalized as previously described (Forster et al., 2005; Burek et al., 2012) . Cells were cultured in phenol-red free Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, # 21063-029) with 10% fetal calf serum (FCS), and 100 U/ml penicillin-streptomycin on plates coated with collagen IV (Fluka) in a humid atmosphere with 5% CO 2 at 37°C. Cells were allowed to reach confluence and were then transfected or treated with 10 À8 M E2 in medium with 1% dextran-coated charcoal FCS as indicated in figure legends.
Transient transfection and reporter gene assay
cEND were seeded on 12-well cell culture plates (Greiner) coated with collagen IV and were grown for five days to confluence. Transient transfection was performed with Effectene reagent (Qiagen) according to the manufacturer's instructions in growth medium with 1% dextran-coated charcoal FCS. Promoter constructs cloned into the pGL3-basic vector (500 ng) and 250 ng of the internal control pTRL-TK encoding Renilla luciferase (Promega) for the estimation of the transfection efficiency were used. Cells were incubated for 24 h and then treated with 10 À8 M E2 or vehicle for 24 h. The cells were lysed and harvested by the Dual-Luciferase reporter assay kit (Promega). Protein concentration was estimated using BCA Protein Assay Kit (Pierce). Luciferase activity was measured with LB 9507 luminometer with dual injector (Berthold Technologies). Each lysate was measured twice. Promoter activities were normalized for protein content and the activity of Renilla luciferase in each extract. The data were calculated as the mean of three or four identical set-ups.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assays were carried out essentially as previously described (Harke et al., 2008) according to the Upstate Biotechnology protocol (Upstate). cEND cells (1 Â 10 8 ) were grown in 10 cm tissue culture plates and were treated with a vehicle or with 10 À8 M E2 for 24 h. Formaldehyde was added to the medium to a final concentration of 1%, and the cells were incubated for 10 min at 37°C. Samples were lysed and sonicated three times for 45 s using a Bandelin Sonopuls Sonifier at 30% of maximum power. The cell lysates were centrifuged at 15,000Âg for 10 min at 4°C. To check the proper shearing of the chromatin, unsheared and sheared chromatin were electrophoresed through a 2% agarose gel (Supplemental Fig. S1 ). The extracts were diluted with ChIP dilution buffer and precleared with 80 ll salmon sperm DNA-protein A agarose slurry (Life Technologies) for 1 h with agitation at 4°C. 10 ll (1%) aliquot of diluted chromatin was saved and used as the input control. Immunoprecipitation was performed over night at 4°C with a rabbit polyclonal IgG against the ERa (MC-20) (Santa Cruz Biotech, sc-542), ERb (H-150) (Santa Cruz Biotech, sc-8974) or normal mouse IgG (Millipore, 12-371B) in the presence of 80 ll of salmon sperm DNA and protein A agarose slurry. Immunoprecipitates were washed once with low-salt, high-salt and LiCl buffers and twice with TE buffer. DNA/protein complexes were eluted twice for 15 min with 1% sodium dodecyl sulfated in 0.1 M NaHCO 3 at room temperature. To reverse the DNA-protein crosslinks, the samples were heated at 65°C for 4 h followed by RNase A (0.05 lg/ll, 30 min at 37°C, Millipore) and proteinase K (0.05 lg/ll, 1 h at 45°C Millipore) digestions. DNA was purified by phenol-chloroform extraction and ethanol precipitation. DNA was amplified by real-time qPCR using the SYBR Ò Green Master Mix (Life Technologies) according to manufacturer's instructions. Two sets of specific and one set of nonspecific primer sequences were used to validate protein binding. Primers were designed using Primer3 Software and synthesized by Eurofins MWG Operon and tested for PCR efficiency. The primer sequences were as follows: pCldn5-ERE forward:
(expected product size 145 bp); nonspecific forward: 5 0 -GGGACC CAGTGTGTCTAACC-3 0 , reverse: 5 0 -TGCCTTGCCATCCTACA AAT-3 0 . The specific regions in claudin-5 promoter to be amplified are separated by 137 bp. The primer produced a single, specific PCR product as confirmed by melting curve in real-time PCR and the sequencing of the PCR products (Eurofins MWG Operon). Data were acquired with the ABI PRISM 7300 system (Life Technologies). The ABI PRISM 7300 SDS software (relative quantification study) was used to determine the threshold cycle (C t ) for each reaction.
Electrophoretic mobility shift assays (EMSA) and super-shift assays
Nuclear extracts were isolated from untreated cEND cells or cEND treated with 10 À8 M E2 for 24 h using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce) according to the manufacturer's instructions. The concentration of nuclear proteins was determined with the BCA Protein Assay Kit (Pierce) and the lysates were stored until use at À80°C. The synthetic oligonucleotides (sense and anti-sense) derived from the mouse claudin-5 promoter, were synthesized by Eurofins MWG Operon. Doublestranded DNA probes were 3 0 end-labeled with biotin using Biotin 3 0 End DNA Labeling Kit (Pierce). The sense sequence of the oligonucleotide containing the putative ERE site (underlined) of mouse claudin-5 promoter was: 5 0 -GTGTAGGTTAGGGGTCATG CTGCTAACAGTGGA-3 0 . The sense sequence of the mutated ERE oligonucleotide was: 5 0 -GTGTAGGTTAGGTTTCATGCTTCTAACAGT GGA-3 0 (mutated base pairs in bold). EMSA was performed using LightShift Ò Chemiluminescent EMSA Kit (Pierce). Three microgram of nuclear extract with protease inhibitors (Roche) and 20 fmol of biotin-labeled-ERE oligonucleotide were used for each binding reaction. A 100-fold excess of unlabeled oligonucleotide competitors was used for the competition experiments. For super-shift reaction 1 lg of a rabbit polyclonal IgG against the ERa (MC-20) (Santa Cruz Biotech, sc-542), ERb (H-150) (Santa Cruz Biotech, sc-8974) or normal mouse IgG (Millipore, 12-371B) was used. The reaction mixture was then loaded onto a 6% or 4% (for super-shift separation) native polyacrylamide gel and electrophoresis was run for 1.5 h at 200 V in 0.5 Â TBE buffer. The protein-DNA complexes were transferred to the Biodyne B Nylon Membrane (Pierce) and UV cross-linked. Detection was made using enhanced chemiluminescence method included in the kit. The images were taken using the FluorChem FC2 Multi-imager II (Alpha Innotech).
Statistical analysis
Data are presented as mean ± standard deviation (SD) from at least three independent experiments. Statistically significant differences between two groups were assessed by student t test (Excel). Comparisons between three and more groups expressed as fold of the control were performed by Kruskal-Wallis one way ANOVA on ranks followed by Student-Newman-Keuls post hoc test (Sigma Stat 3.1). P values less than 0.05 were considered statistically significant.
Results
Functional analysis of potential binding sites for estrogen receptors in À500/+111 murine claudin-5 promoter constructs
As already published previously, claudin-5 promoter sequence contains in the first 500 nucleotides two potential binding sites for estrogen receptors (Burek and Forster, 2009) . One of them is an imperfect ERE and the other one close to the transcription start site is a Sp1 binding site (Fig. 1A) . Two different mutations of potential ERE site including one with a three-nucleotide change (mutERE1) and one with a two-nucleotide change (mutERE2), as well as a potential Sp1 binding site with a two-nucleotide change were generated (Fig. 1A) using the À500/+111 construct. These constructs were subjected to reporter gene assays in comparison to an empty pGL3-basic vector or wild type À500/+111 construct. Estimation of a basal transcriptional activity of those constructs showed a decrease for all three mutated fragments in comparison to a wild type construct (Fig. 1B) . The basal transcriptional activity of mutERE1 was 1.5 ± 0.68-fold (p > 0.05), mutERE2 was 0.88 ± 0.03-fold (p < 0.05) and mutSp1 2.2 ± 0.44-fold (p < 0.05) and of the wild type (wt) construct 6.2 ± 0.95-fold (p < 0.05) as compared to a signal given by pGL3-basic vector which was set as 1.
Next, we compared the transcriptional activity of wt and mutated constructs after E2 treatment (Fig. 1C) . The wt construct showed a 2.9 ± 0.25-fold (p < 0.05) activation, whereas the mutated forms of ERE showed no significant changes of the transcriptional activity (mutERE1 showed activation 0.9 ± 0.15-fold and mutERE2 0.8 ± 0.30-fold) as compared to untreated controls set as 1. However, mutSp1, containing native ERE, showed 1.7 ± 0.54-fold (non-significant) activation after E2 treatment in comparison to the untreated control (Fig. 1C) . In addition, we transiently transfected the wt À500/+111 claudin-5 promoter construct into the ERnegative NIH3T3 cell line (Supplemental Fig. S2 ) and performed reporter gene assays (Bahadur et al., 2005) . E2 did not induce claudin-5 promoter in the absence of co-transfection with ER a and ERb. However, in the presence of ERa and ERb expressing vectors, activity of the promoter was significantly induced by 1.5 ± 0.12-fold (p < 0.05). These data suggest that the expression of ER subtypes is indispensable for the hormonal activation of the claudin-5 promoter.
To further elucidate the role of potential Sp1-binding site in E2-mediated transcription, we used a truncated form of the claudin-5 promoter, a À267/+111 construct. This construct does not contain the ERE site, only the Sp1 binding site is present (Fig. 2) . After introducing the mutation into a Sp1-binding site, we performed basal activity measurements in comparison to a wild type and pGL3-basic vector. The wt À267/+111 construct showed high basal transcriptional activity, which was 4.4 ± 0.68-fold (p < 0.05) higher than the activity of pGL3-basic vector. In contrast, the Sp1 mutation in À267/+111 construct abrogated the basal transcriptional activity (Fig. 2A) . Treatment with E2 induced the wt À267/+111 construct 2.5 ± 0.14-fold (p < 0.05) and the mutSp1 1.1 ± 0.06-fold (p > 0.05) in comparison to untreated controls. Thus, mutation of Sp1 binding site in the absence of functional ERE site leads to a loss of transcriptional activity of claudin-5 promoter.
Interactions of ERa and ERb with claudin-5 promoter in chromatin immunoprecipitation assay
In previous studies, we demonstrated using ERb-knockout mice, the role of ERb in the regulation of claudin-5 expression in the brain (Burek et al., 2010) . In those experiments the involvement of ERa could not be excluded. Here, we performed chromatin immunoprecipitation (ChIP) experiments using anti-ERa and ERb antibodies and amplifying by real-time qPCR the fragments with potential binding sites for ER and one unrelated fragment (Fig. 3) . We performed the experiments using E2-treated and untreated cEND cells, since these cells express high levels of claudin-5 and mimic the physiological state and transcriptional regulation of genes in brain microvascular endothelial cells in vivo. To control the specificity of the qPCR, the claudin-5 promoter fragments immunoprecipitated with ERa and ERb antibody and amplified with specific primers were sequenced.
In the qPCR reaction with primer pair Cldn5-ERE, which amplifies the claudin-5 promoter fragment containing ERE, E2 treatment of cEND cells caused recruitment of both ERa and ERb to the claudin-5 promoter (Fig. 3A) . Similarly, using the Cldn5-Sp1 primer pair amplifying the GC-rich site containing promoter fragment, we detected the specific products in both immunoprecipitation reactions with anti-ERa and anti-ERb (Fig. 3B) . As a control for a binding specificity of ER subtypes, qPCR with primers targeting a nonspecific region within the claudin-5 gene was carried out (Fig. 3C ). This control showed that there was no binding within this nonspecific area. This data suggests that E2 activates claudin-5 through the cooperative ERE/Sp1 site interactions of estrogen receptors and Sp1. Fig. 1 . Mutations of putative estrogen response element in À500/+111 mouse claudin-5 promoter construct diminish the transcriptional activity. A. Nucleotide sequence of consensus estrogen response element (ERE) and putative ERE and Sp1 binding site in mouse claudin-5 promoter. Mutated forms mutERE1, mutERE2 and mutSp1 are shown in the bottom. Mutated nucleotides are in bold. B. Basal transcriptional activity of wild type and mutated À500/+111 claudin-5 promoter construct. The promoterless pGL3-basic vector fused to luciferase (luc) gene was used as reporter vector. cEND were transfected with À500/+111 wild type (wt) or mutated forms of À500/+111 construct mutERE1, mutERE2, mutSp1. 24 h later the cells were lysed and luciferese activity was measured. Each transfection reaction in an assay was carried out in triplicate and assays were repeated four times. Values are normalized for protein content and expression of co-transfected Renilla luciferase reporter gene. Data (means ± standard deviation) are expressed as fold over pGL3-basic, which was arbitrarily set as 1. ( Ã ) p < 0.05 calculated with ANOVA on ranks and Student-Newman-Keuls post hoc test. C.
Transcriptional activity of a wild type and mutated À500/+111 claudin-5 promoter construct after treatment with 17b-estradiol. cEND cells were transfected with wild type (wt) and mutated À500/+111 promoter construct and 24 h later were treated with 10 À8 M 17b-estradiol (E2) or vehicle only for the next 24 h. Each transfection reaction in an assay was carried out in triplicate and assays were repeated three times. Values are normalized for protein content and expression of co-transfected Renilla luciferase reporter gene. Data (means ± standard deviation) are expressed as fold over vehicle treated control, which was arbitrarily set as 1. ( Ã ) p < 0.05 calculated with Student's t-test.
Electrophoretic mobility shift assay shows binding of ERa and ERb to the imperfect ERE site in claudin-5 promoter
We could demonstrate that the imperfect ERE in the claudin-5 promoter plays an important role in E2-mediated transactivation of claudin-5 promoter. In order to further confirm the results obtained with the reporter gene assays and ChIP, we performed an electorphoretic mobility shift assay (EMSA) using biotinylated nucleotides containing claudin-5 promoter putative ERE site (Fig. 4) . Interaction between the ER proteins was investigated by incubating nuclear extracts form cEND treated with 10 À8 M E2 for 24 h with biotin-labeled ERE oligonucleotide as described in Materials and Methods. Nuclear extract from cEND formed a retarded complex (Fig. 4A, lane 2) indicating binding of proteins to this DNA fragment. In competition experiments, the intensity of the retarded DNA-complex was decreased after pre-incubation of nuclear lysates with the unlabelled ERE-nucleotides (Fig. 4A,  lane 3) . Competing unlabeled oligo led to a lower incorporation of biotinylated nucleotides into the protein-chromatin complexes, showing only a faint band corresponding to protein-bound nucleotides and at the bottom of the gel more unbound biotinylated oligonucleotides (free oligo). Super-shift analysis with antibody against ERa or ERb was performed to determine the role of ER subtypes in the formation of ERE/protein complex (Fig. 4B) . To obtain a better separation of the shifted bands, 4% native gels were used and the free biotin-oligonucleotides ran out of the gel (lanes 1 and 4). Super-shift bands (lanes 3 and 6) were observed above the retarded ERE-biotin/protein complexes (lanes 2 and 5). No super-shift was observed with nuclear extracts from untreated cEND cells (Fig. S3 ). This indicates that ER-binding to claudin-5 promoter ERE is ligand dependent. Incubation of nuclear extracts with normal mouse IgG failed to form a super-shift. Moreover, the antibodies were not unable to bind the mutated ERE oligonucleotide (Fig. S3) . These results confirmed the role of both ERa and ERb proteins in formation of the specific retarded band using an ERE-biotin oligonucleotide.
Discussion
Estrogen-mediated regulation of claudin-5 led to an increase in the claudin-5 protein expression and to an increase in the transendothelial electrical resistance of endothelial cell monolayer in vitro. Moreover, ERb knockout mice showed lower mRNA expression and protein levels of claudin-5 in the brain capillaries (Burek et al., 2010) . The increase in claudin-5 protein has been shown to be beneficial in different pathological disorders and this strategy bears a therapeutic potential (Kleinschnitz et al., 2011; Campbell et al., 2012) . We decided to study the mechanism of E2-mediated claudin-5 regulation in detail through identifying the promoter fragments of claudin-5 involved in estrogenmediated regulation. Using mutation/deletion analysis of the promoter in reporter gene assay, ChIP and EMSA we demonstrate that the non-consensus ERE and Sp1 close to transcription start site are functional and responsible for E2 effects on claudin-5 expression.
As a cell line of choice we used the cEND cells, the immortalized brain microvascular endothelial cells isolated and characterized previously (Forster et al., 2005) . These cells retain BBB characteristics and express endothelial and BBB markers, such as VE-cadherin, occludin, claudin-5 and ZO-1. The expression of both ER subtypes was confirmed in cEND previously (Burek et al., 2010) . Accordingly, treatment of cEND with E2 resulted in increased barrier properties (increased transendothelial electrical resistance) and induction of tight junction proteins occludin and claudin-5 as well as VE-cadherin expression. The E2-mediated effects on claudin-5 were blocked by co-administration of the nonselective ER antagonist ICI 182.780 suggesting the involvement of genomic actions of estrogen in claudin-5 regulation (Burek et al., 2010) . These previous studies demonstrated that the cEND might be a suitable cellular model to study in detail the E2-mediated regulation of the claudin-5 promoter.
Analysis of the claudin-5 promoter sequence revealed a nonconsensus ERE at the position À303/À289 (5 0 -GGGTCATGCTGC TAA-3 0 ) and a GC-rich sequence, a Sp1 site at the position À57/À47 (5 0 -TGGGGGCAGAG-3 0 ) (Burek and Forster, 2009) . In a number of E2-regulated promoters, a cooperative ER/Sp1 regulation have been described, e.g., cathepsin D, heat shock protein 27 (Hsp27), trefoil factor 1 (TFF1), PSa gene (PROS1), progesterone receptor (PR), metastasis-associated protein 3 (Mta3), Lpr16, transforming growth factor a (Tgfa), telomerase or uteroglobin promoter (Krishnan et al., 1994; Porter et al., 1996; Scholz et al., 1998; Vyhlidal et al., 2000; Fujita et al., 2004; Sun et al., 2005; Zhao et al., 2005; Boggess et al., 2006; Suzuki et al., 2010) . The number of nucleotides separating the ERE and Sp1 elements differs in all this genes from 3 in telomerase promoter to 68 in Mta3 promoter (Fujita et al., 2004; Boggess et al., 2006; Safe and Kim, 2008) . The ERE and Sp1 site in the claudin-5 promoter are separated by 232 nucleotides, so it might be expected that the regulatory proteins bind on both elements. Mutations of the ERE led to a strong decrease in a basal transcriptional activity of this promoter fragment. The construct with the mutated Sp1 site and the intact ERE, showed also a decreased basal transcriptional activity, but to a lesser extent. All the constructs with mutated ERE showed significantly lower basal activity. Thus, the intact ERE is important for a basal transcriptional activity of claudin-5 promoter. Moreover, in E2 treatment experiments, it has been demonstrated that only one point mutation in the palindromic sequence of ERE is sufficient to abrogate the E2-mediated induction of the claudin-5 promoter. Functioning ERE site in the claudin-5 promoter can thus be assumed as necessary for the E2-mediated activation of the claudin-5 promoter. The E2-induction of the wild type constructs was 2.9-fold over the untreated control. The E2-induction achieved in cEND in a previous study was 3.7-fold over the untreated control (Burek et al., 2010) . Discrepancy of this data may result from the cellular system itself as well as the technical differences in the transient transfection method. Immortalized brain endothelial cells are known to change their properties during the culture as observed also for other in vitro blood-brain barrier models . Besides the low wt construct induction, the relevance of the deletion/mutation study can be strengthened by the fact that only in the presence of ER E2-induction can be achieved as shown in NIH3T3 cells that lack estrogen receptors (Fig. S2) (Bahadur et al., 2005) .
The functional Sp1 site in combination with mutated ERE site was not sufficient to significantly induce transcriptional activity. However, wild type ERE site could still transduce the E2 effects, when the Sp1 binding site was mutated. Since the truncated À267/+111 claudin-5 promoter construct shows high basal activity as well as a significant E2 induction, there might be some negative influence of mutated ERE in the À500/+111 construct with an intact Sp1 site, as this construct does not show a significant E2 induction. Only the truncated form of the promoter with mutated Sp1 binding site finally abrogated the transcriptional activity. This demonstrates that Sp1 binding site contributes to E2 signaling and an ERE need not to be present for E2-mediated transcription activation. Sp1 site thus alone confer estrogen responsiveness of claudin-5 promoter. Such ER regulation has been described for many genes in breast cancer cells, but only a few examples are known form other cell types (Safe and Kim, 2008) . Sp1 site function independently of an ERE also in Bcl-2, adenosine deaminase, vascular endothelial growth factor, DNA polymerase a and insulin-like growth factor-binding protein-4 promoters (Dong et al., 1999; Qin et al., 1999; Xie et al., 1999; Stoner et al., 2000; Samudio et al., 2001) . The results obtained with ChIP are consistent with the reporter gene assays. We showed that both ER subtypes are recruited to ERE and Sp1 site in the claudin-5 promoter. The involvement of Sp1 protein was not tested.
Gel mobility shift assays were used to investigate formation of an ER complex with the biotin-labeled ERE oligonucleotide derived from the claudin-5 promoter. Incubation of nuclear extracts form cEND cells with ERE-biotin resulted in formation of a DNA-bound retarded complex. The unlabeled ERE-oligonucleotide competitively decreased formation of this complex. The association of both ER subtypes with the DNA-protein complex was further confirmed using ERa and ERb antibodies in super-shift formation. No supershift was observed with normal mouse IgG, mutated ERE-oligonucleotide or with nuclear extracts from untreated cEND cells (Fig. S3 ). Both ER subtypes are expressed in the cardiovascular system. After estrogen binding to the receptors, they translocate into the nucleus and bind to the chromatin to activate the transcription of their target genes. ERs can build homodimers as well as heterodimers (Pettersson and Gustafsson, 2001) . In case of the ERE in claudin-5 promoter sequence we could indentify both ER subtypes binding using ChIP and EMSA. ER can also activate the transcription of genes through other transcription factors, such as Ap1 or Sp1 (Safe and Kim, 2008) . This could be the case for a truncated claudin-5 promoter form, where only the putative Sp1-binding site is present. At this site we detected in the ChIP the binding of both ER subtypes, ERa and ERb. ERb has been shown in literature to build complexes with Sp1 transcription factor, and these complexes appeared to be functional (Guido et al., 2012) . Also a deficiency of ERb decreases the level of claudin-5 in mouse brain capillaries as demonstrated in previous study (Burek et al., 2010) . In addition to ER-mediated regulation of claudin-5, the Sox18 transcription factor has been shown to induce the claudin-5 promoter and to increase the claudin-5 expression leading to an improvement in BBB properties (Fontijn et al., 2008) . Putative binding sites for NFjB have been identified in mouse claudin-5 promoter (Burek and Forster, 2009) . Indeed, treatment with a cytokine TNFa, a ligand in the NFjB signaling pathway, led to a repression of claudin-5 expression (Burek and Forster, 2009; Aslam et al., 2012) . b-catenin and transcription factor FoxO1 also bind to a claudin-5 promoter and inhibit its transcription, in the presence of pro-permeability factors like VEGF or reactive oxygen species (Taddei et al., 2008) . ETS-related gene (ERG) binds the claudin-5 promoter and regulates endothelial permeability (Yuan et al., 2012) . Since claudin-5 is expressed ubiquitously in the vasculature, the therapeutic manipulations of its expression would have global effects in the organisms. In case of estrogen-mediated claudin-5 regulation, the existing tissue specific agonists SERMS (selective estrogen receptor modulators) for ERs could be used to modulate the expression of claudin-5 only in the desired tissue. In the brain, increase of claudin-5 expression would be beneficial in all disorders where the BBB is compromised, such as multiple sclerosis or stroke.
Taken together, our results show in detail the molecular mechanisms of estrogen-mediated claudin-5 expression and identify the promoter fragments responsible for this regulation.
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